Navigation Links
Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand

- Neptune Technologies & Bioressources Inc. enters into an exclusive distribution agreement with AZPA International Inc. for Australia and New

Zealand -

LAVAL, QC, Dec. 19 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce that it has entered into an exclusive distribution agreement with AZPA International Inc. ("AZPA International") for Australia and New Zealand. AZPA International, a leading supplier to the pharmaceutical, nutritional health and cosmetics industries, has also acquired non-exclusive rights to commercialize Neptune's products in Southeast Asia and Hong Kong.

The nationwide product launch of Neptune Krill Oil (NKO(R)) in Australia and New Zealand, claiming cardiovascular and joint health benefits, is scheduled for February 2008. A pre-requisite for commercializing NKO(R) in Australia hence New Zealand is obtaining approval as a complementary medicine from the Therapeutic Goods Administration (TGA) which notification Neptune has recently announced.

AZPA International joined forces for the commercialization and distribution of NKO(R) with PharmaLink Pte. Ltd. ("PharmaLink"), a leading provider of complementary and over-the-counter medicines and a leader in healthcare sales and marketing in the Asia-Pacific region. PharmaLink will be reaching the market through its primary care team, its pharmacy/ OTC team and its specialist/ allied health team.

"It is estimated that 74% of the Australian population has used complementary medicine in the previous twelve months and usage rates are expected to rise,(1)" said Thierry Houillon, Vice President of Nutraceuticals of Neptune. "An estimated annual increase of 18% has been reported for the complementary medicine market in Australia.(2) We are looking forward to working with AZPA International and PharmaLink benefiting from this trend and making NKO(R) a household name in Australia and New Zealand," he added.

PharmaLink, in collaboration with AZPA International, will also prepare a comprehensive marketing campaign, including medical conventions, tradeshows, and extensive press and mass media coverage. Selected consumers will be taking NKO(R) for a period of three months and will subsequently be reporting on radio & TV talk shows about their experience with NKO(R).

In addition, AZPA International will be working with Lipa Pharmaceuticals, Australia's leading contract manufacturer to the nutritional and pharmaceutical industries, which makes products in key growth areas of complementary and alternative medicines, over-the-counter (OTC) and prescription pharmaceuticals.

1. Source: Cardinal Health. Vitamin, Mineral, Herbal and Nutritional

Supplements, 4 October 2005

2. Source: Complementary Healthcare Council communication, 13 September


About Neptune Technologies & Bioressources Inc.

Neptune develops proprietary health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, the Company is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

Neptune continues to strongly support its strategic development plan to form partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. Neptune has recently signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, paving its entrance into the global functional food market. According to its business strategy, negotiations with pharmaceutical companies with the objective of entering the pharmaceutical market by licensing rights are ongoing.

NASDAQ and TSX venture exchange does not accept responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted
2. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
3. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
4. Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008
5. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
6. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
7. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
Post Your Comments:
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
(Date:10/9/2017)... Texas (PRWEB) , ... October ... ... study published on October 5, 2017, in the medical journal, Epilepsia, Brain ... with the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) ...
(Date:10/7/2017)... , Oct. 6, 2017  The 2017 ... of three scientists, Jacques Dubochet, Joachim Frank ... developments in cryo-electron microscopy (cryo-EM) have ... within the structural biology community. The winners worked ... can now routinely produce highly resolved, three-dimensional images ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the ... from around the world, is giving back to cancer research with a month-long promotion ... , Now through October 31, shoppers can use promo code PinkRibbon to get 10 ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):